The model group was fed 0.2% adenine diet for 14 days to establish CKD model, while the treatment group was treated with AhR antagonist CH223191. AhR agonist kynurenine and antagonist CH223191 was applied in mouse tubular epithelial (TCMK-1) cells to investigate the underlying mechanisms of ...
Provided herein is a therapeutic composition that comprises an aryl hydrocarbon receptor (AhR) antagonist and an SRC inhibitor. In one embodiment, the therapeutic composition further comprises a pharmaceutical excipient. In one embodiment, the AhR antagonist is CH223191 and the SRC inhibitor is PP2 ...
Also when treated with an AhR antagonist aNF there is a corresponding decrease in these levels (Fig. 4A). This suggests that AhR can control unsaturated fatty acid metabolism, and up regulate beneficial lipid molecules in RPE cells. Notably one of the MUFA lipids that is up regulated by ...
To test whether the induction of suppressive T cells by ITE was mediated by AHR, we targeted AHR using small interfering RNA (siRNA) that abrogated the suppressive effect of ITE and then corroborated these findings using a selective AHR antagonist CH223191 that also blocked ITE-mediated ...
pathway to the neuronal toxicity, red seabream embryos at 10 h post-fertilization (hpf) were treated for 80 min with \\{TCDD\\} (0, 0.3, 5.3, and 37 nM in seawater) alone or in combination with \\{CH223191\\} (500 nM in seawater), which is an \\{AHR\\} antagonist...
The CXCR4 antagonist AMD3100, 4-hydroxytamoxifen and 3-methylcholanthrene were purchased from Sigma Aldrich. CH223191 was purchased from Tocris Bioscience (Ellisville, MO, USA). SR1 and SR2 compounds were prepared as described (Bouchez et al, 2011). Cancer drug resistance and metabolism PCR ...
The suppression of TCDD-induced \{CYP1A\} expression by \{CH223191\} treatment was observed in embryos at 24 and 48 hpf, while the effect of the rsAHR antagonist disappeared at 96 and 120 hpf. This phenomenon indicated the transient suppression of TCDD-induced rsAHR activation by \{CH22...
Importantly, the AhR antagonist CH223191 effectively mitigated EOM-induced oxidative stress and cellular senescence. In conclusion, our results indicate that PM2.5-induced AhR activation leads to oxidative stress, DNA damage, and cell cycle arrest, leading to cardiac senescence. Targeting the AhR/ROS...
Provided herein is a therapeutic composition that comprises an aryl hydrocarbon receptor (AhR) antagonist and an SRC inhibitor. In one embodiment, the therapeutic composition further comprises a pharmaceutical excipient. In one embodiment, the AhR antagonist is CH223191 and the SRC inhibitor is PP2 ...
Provided herein is a therapeutic composition that comprises an aryl hydrocarbon receptor (AhR) antagonist and an SRC inhibitor. In one embodiment, the therapeutic composition further comprises a pharmaceutical excipient. In one embodiment, the AhR antagonist is CH223191 and the SRC inhibitor is PP2 ...